JPMorgan discloses Kangji Medical share dealings amidst privatization

On September 11, 2025, JPMorgan Securities PLC, an associate connected with the Offeror, disclosed its dealings in Kangji Medical Holdings Limited shares. These transactions were made for its own account as part of hedging Delta 1 products created from wholly unsolicited client-driven orders, amidst the ongoing privatization by way of scheme of arrangement.

The firm executed two purchase transactions on the specified date. The first involved 194,500 shares, with a total amount paid of $1,721,203.2400. The highest and lowest prices paid per share were both $8.8494. The second transaction saw the purchase of 4,500 shares for a total of $39,623.1700, with both the highest and lowest prices paid per share recorded at $8.8051.

These disclosures were made public pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers. The dealings primarily involved other types of securities, specifically equity swaps.